Interview: AstraZeneca ‘Is More Than Oncology’

AZ’s BioPharma Unit Head Points To CVRM And Respiratory Promise

Ruud Dobber oversees AstraZeneca’s biopharmaceuticals division, which generates some 40% of group total revenues. He tells Scrip to “Watch this space.”

Three_Pipes
AstraZeneca’s Three Therapy Areas Are Cancer, CVRM and Respiratory • Source: Shutterstock

While clearly enjoying the rewards of its a strengthening oncology portfolio, AstraZeneca PLC also used its third-quarter results update 24 October to stress that its two other therapeutic pillars - respiratory and CVRM - are performing well and hold great promise.

“Yes, we are very proud of our oncology performance at AstraZeneca, but equally we’re trying to signal that AstraZeneca is...

More from Business

More from Scrip